HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Adimab announces new discovery collaboration with Kyowa Hakko Kirin
Adimab, LLC, a technology leader in the discovery of fully human antibodies, announced a two-target funded discovery collaboration with Kyowa Hakko Kirin (KHK) of Tokyo, Japan. Based on the strength and flexibility of Adimab's platform, KHK has designated a membrane protein target as the initial collaboration target. In addition, Adimab announced the receipt of milestone payments from its existing collaborations with Gilead, Biogen Idec and Novo Nordisk.

“We are pleased to announce another major pharma partnership,” said Tillman Gerngross, CEO and co-founder of Adimab. “While other technology companies have diverted their focus by developing an internal pipeline of therapeutic products, we have committed all our resources to offering our customers the best discovery technology in the industry.”

Adimab and KHK have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against two targets selected by KHK. For each target, the agreement grants KHK the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, KHK will have the sole option to exclusively license antibodies from the collaboration, and if KHK were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.

In addition, Adimab announced the achievement of technical milestones from its ongoing collaborations with Biogen Idec, Gilead, and Novo Nordisk.

“Adimab continues to see significant interest in our platform from new companies, and this is directly related to the success we have had in our existing partnerships,” said Guy Van Meter, Vice President of Business Development at Adimab. “Speed is always a factor in antibody discovery, but the ability to consistently deliver where other technologies have failed is just as important. Fortunately, we can do both.”

Over the past three and a half years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead and Kyowa Hakko Kirin.

Click here for the complete issue.

NEWS CRUNCH  
news Collaboration is Cure for Better Global Health Outcomes, UK-India Experts Say
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy